Navigation Links
NewCardio Announces Positive Results From Third Clinical Validation Study
Date:8/13/2008

hese statements are based on current expectations, estimates and projections about our business based on currently available information and assumptions made by management. Although we believe that the assumptions on which the forward-looking statements contained herein are based are reasonable, any of those assumptions could prove to be inaccurate given the inherent uncertainties as to the occurrence or nonoccurrence of future events. These statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict. Therefore, actual outcomes and results may, and are likely to, differ materially from what is expressed or forecasted in the forward-looking statements due to numerous factors, including the potential risks and uncertainties set forth in Item 1A of our Annual Report on Form 10-K/A (No. 1) for the year ended December 31, 2007 and relate to our business plan, our business strategy, development of our proprietary technology platform and our products, timing of such development, timing and results of clinical trials, level and timing of FDA regulatory clearance or review, market acceptance of our products, protection of our intellectual property, implementation of our strategic, operating and people initiatives, benefits to be derived from personnel and directors, ability to commercialize our products, our assumptions regarding cash flow from operations and cash on-hand, the amount and timing of operating costs and capital expenditures relating to the expansion of our business, operations and infrastructure, implementation of marketing programs, our key agreements and strategic alliances, our ability to obtain additional capital as, and when, needed, and on acceptable terms and general economic conditions specific to our industry, any of which could impact sales, costs and expenses and/or planned strategies and timing. We assume no obligation to, and do not currently intend to, update these forward-looking statement
'/>"/>
SOURCE NewCardio, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Medarex Announces Initiation of Phase 2 Clinical Development Program for the Treatment of Lupus
2. Lixte Biotechnology Holdings Announces Filing of a New Patent Application for the Use of Novel Compounds as Potential Treatment for Neurodegenerative Diseases
3. Cell Therapeutics Announces that the European Organization for Research and Treatment of Cancer Completes Enrollment in Phase II Clinical Trial of Brostallicin as First Line Therapy for Advanced or Metastatic Soft Tissue Sarcoma
4. Lixte Biotechnology Holdings Announces That Novel Compounds Being Developed as Potential Treatments for Brain Tumors Have Positive Activity in a Mouse Model of Human Pancreatic Cancer
5. Innocoll Announces Dosing of Last Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-Operative Pain
6. Amicus Therapeutics Announces Second Quarter 2008 Financial Results
7. Oramed Pharmaceuticals Announces Successful Phase 2A Clinical Trial of its Oral Insulin Capsule
8. Rib-X Pharmaceuticals, Inc. Announces Recent and Upcoming Presentations at Scientific Conferences
9. Tolerx Announces Achievement of Milestones upon anti-CD4 Antibody Program Advancement and Initiation of Phase 1 Clinical Trial
10. Medarex Announces Allowance of Investigational New Drug Application for Wholly-Owned Fully Human Anti-PD-L1 Antibody, MDX-1105
11. Cara Therapeutics Announces Successful Completion of Phase I Clinical Trial of Novel Analgesic, CR845
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... DIEGO , May 4, 2015 ... oncology company focused on the clinical development of ... data showing mitochondria-specific effects of the Company,s investigational ... enhanced anti-tumor activity when combined with a tyrosine-kinase ... found ME-344 to be a potent inhibitor of ...
(Date:5/4/2015)... the cuvette manufacturing world, opened their doors to the public in early 2015.  In ... scientists amazing support for their spectroscopy needs.  ... ... ... In mid-2014 Simcha Woitovich ...
(Date:5/4/2015)... May 4, 2015 Dyadic International, Inc. ... patented and proprietary technologies are used to develop, ... the bioenergy, bio-based chemical, biopharmaceutical and industrial enzyme ... financial results for quarter ending March 31, 2015 ... and will host a conference call that day ...
Breaking Medicine Technology:MEI Pharma's Mitochondrial Inhibitor ME-344 Shows Enhanced Anti-Tumor Activity in Combination with Tyrosine-Kinase Inhibitor in Pre-Clinical Studies 2MEI Pharma's Mitochondrial Inhibitor ME-344 Shows Enhanced Anti-Tumor Activity in Combination with Tyrosine-Kinase Inhibitor in Pre-Clinical Studies 3MEI Pharma's Mitochondrial Inhibitor ME-344 Shows Enhanced Anti-Tumor Activity in Combination with Tyrosine-Kinase Inhibitor in Pre-Clinical Studies 4MEI Pharma's Mitochondrial Inhibitor ME-344 Shows Enhanced Anti-Tumor Activity in Combination with Tyrosine-Kinase Inhibitor in Pre-Clinical Studies 5New Cuvette Manufacturer Delivers Fast, Easy Solutions for Even the Hardest Cuvette Experiments 2New Cuvette Manufacturer Delivers Fast, Easy Solutions for Even the Hardest Cuvette Experiments 3Dyadic International To Announce First Quarter 2015 Financial Results and Host Conference Call On Thursday, May 14, 2015 2Dyadic International To Announce First Quarter 2015 Financial Results and Host Conference Call On Thursday, May 14, 2015 3
(Date:5/4/2015)... Washington, DC (PRWEB) May 04, 2015 ... of Kit Check as a finalist for the EY ... Washington Region. The awards program recognizes entrepreneurs who ... innovation, financial performance and personal commitment to their businesses ... finalist by a panel of independent judges. Award ...
(Date:5/4/2015)... Ticket Down is a reputable source for ... in Columbia, South Carolina. Fans of Paul McCartney ... There” tour which originally kicked off in 2013. The most ... and the legendary performer recently announced that he would be ... on June 21st, in Charlottesville, VA at John Paul Jones ...
(Date:5/4/2015)... San Diego Fertility Center (SDFC) ... new, 13,700 square foot facility scheduled to open in ... only provide fertility treatment and services for the center’s ... educational events to a number of local and international ... to their current Carmel Valley/Del Mar location and will ...
(Date:5/4/2015)... Rafael, CA (PRWEB) May 04, 2015 Unlike some ... foremost on imparting knowledge. The goal is to educate first ... the classroom. This ensures that the young runners are building ... careers. A few of the topics covered include Effort Based ... fast as I used to be? This is not a ...
(Date:5/4/2015)... May 04, 2015 Sylvia Hawthorn-Deppen shared her ... that it would remind others in similar situations that they ... from Chronic Pain and Discovery of New Energy” (published by ... new audience via a renewed press campaign. , “I have ... debilitating pain ,” Hawthorn-Deppen says. “As an adolescent I got ...
Breaking Medicine News(10 mins):Health News:EY announces Kit Check CEO and Co-founder Kevin MacDonald as an EY Entrepreneur Of The Year® 2015 Award finalist in the Greater Washington Region 2Health News:Paul McCartney Tickets at Colonial Life Arena in Columbia, SC: Ticket Down Slashes Paul McCartney Ticket Prices in Columbia, South Carolina at Colonial Life Arena 2Health News:San Diego Fertility Center Hosted a Ribbon Cutting Ceremony at Its New, Expanded Facility 2Health News:San Diego Fertility Center Hosted a Ribbon Cutting Ceremony at Its New, Expanded Facility 3Health News:US Sports Camps and Select Nike Running Camps Offer Programs for Middle School Runners 2Health News:Author launches new press campaign for 2012 book ‘Wheel’ 2
... Nov. 21 Attorneys representing consumers and,third-party payers ... healthcare services giant McKesson (NYSE: MCK ... price of more than 400 prescription drugs by,manipulating ... (Logo: http://www.newscom.com/cgi-bin/prnh/20080317/AQM144LOGO ) , ...
... 21 DATATRAK,International, Inc. (Nasdaq: DATA ... eClinical solutions for the clinical trials industry, today ... Corporation, has placed its first,self-designed project using the ... trial. The successful rollout of this first,independently ...
... VICL ) today announced a strategic restructuring ... the company,s total workforce,and accelerated closure of a research ... employees and expects to reduce future,net losses and cash ... The restructuring is designed to ...
... to a relationship between erectile dysfunction and prostate enlargement. Because of ... to increase the treatment of BPH in men. The focus of ... (ED). Dr. Eid will continue with ED treatments while building his ... ...
... prestigious "Super Dentist" award given to elite dentists in Texas. Dr. ... in the area of Cosmetic Dentistry. , ... Austin, ... Smiles was recently nominated as a "Texas Monthly Super Dentist" ...
... that timing is everything, and that certainly appears to be ... before the height of cold and flu season have a ... any other time of year, according to new research. ... more than 95,000 children and their mothers in Tennessee to ...
Cached Medicine News:Health News:Hagens Berman Sobol Shapiro: McKesson Settles RICO Lawsuit for $350 Million 2Health News:Hagens Berman Sobol Shapiro: McKesson Settles RICO Lawsuit for $350 Million 3Health News:NTT DATA Launches First Self-Designed DATATRAK eClinical(TM) Project Into Production in Japan 2Health News:NTT DATA Launches First Self-Designed DATATRAK eClinical(TM) Project Into Production in Japan 3Health News:Vical Announces Strategic Restructuring and Staff Reduction 2Health News:Vical Announces Strategic Restructuring and Staff Reduction 3Health News:World-Renowned Urologist, J. Francois Eid, M.D., Expands Practice with Increased Treatment of Benign Prostate Hyperplasia (BPH) 2Health News:World-Renowned Urologist, J. Francois Eid, M.D., Expands Practice with Increased Treatment of Benign Prostate Hyperplasia (BPH) 3Health News:World-Renowned Urologist, J. Francois Eid, M.D., Expands Practice with Increased Treatment of Benign Prostate Hyperplasia (BPH) 4Health News:Texas Super Dentist Awards Announced--Dr. Michael McCarty From Austin Smiles Is Awarded For The Third Year In A Row 2Health News:Fall babies: Born to wheeze? 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: